Boston Scientific Acquires SoniVie for $360M, Up to $540M Total

Boston Scientific has announced its acquisition of SoniVie Ltd. for $360 million upfront, with potential additional payments of up to $180 million based on regulatory milestones. The acquisition is aimed at enhancing Boston Scientific's interventional cardiology portfolio, particularly through SoniVie's investigational TIVUS Intravascular Ultrasound System, which seeks to treat hypertension by targeting nerves surrounding blood vessels. This system represents an innovative approach to renal artery denervation, as it utilizes ultrasound technology that could offer deeper tissue penetration compared to traditional methods. The deal aligns with Boston Scientific's ongoing strategy to expand its market presence, following several other acquisitions within the medical device sector. The acquisition is expected to close in the first half of 2025. Lance Bates, the senior vice president of Interventional Cardiology Therapies at Boston Scientific, emphasized the potential of the TIVUS system to provide a minimally invasive therapy for hypertension patients.